With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 36812887.
- Also identified by DOI 10.1016/j.xcrm.2023.100950 and PMC identifier 9975326.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mutation-selective KRAS inhibitors are revolutionizing the treatment of RAS-mutant tumors but cannot achieve durable effects alone. Kemp and colleagues<sup>1</sup> recently showed how the KRAS-G12D-specific inhibitor MRTX1133, while impairing cancer proliferation, stimulates T cell infiltration, which is crucial for sustained disease control.
Medical subject headings
- T-Lymphocytes
- Proto-Oncogene Proteins p21(ras)